Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered ...

The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

Fintel reports that on June 20, 2025, William Blair downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, ...